Myeloma in Elderly Patients: When Less Is More and More Is More

Ashley Rosko, Sergio Giralt, Maria Victoria Mateos, Angela Dispenzieri

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.

Original languageEnglish (US)
Pages (from-to)575-585
Number of pages11
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
StatePublished - 2017

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Myeloma in Elderly Patients: When Less Is More and More Is More'. Together they form a unique fingerprint.

Cite this